Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma
- 7 July 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 91 (10), 1354-1360
- https://doi.org/10.1002/bjs.4594
Abstract
Background: Vascular endothelial growth factor (VEGF) and endostatin stimulate and inhibit tumour angiogenesis respectively. Recent studies have demonstrated the prognostic value of serum levels of both VEGF and endostatin in patients with various types of cancer. Their significance in patients with hepatocellular carcinoma (HCC) remains unclear. Methods: Serum VEGF and endostatin levels were measured by enzyme immunoassay in 108 patients with HCC before surgical resection and in 20 healthy controls. Preoperative serum VEGF and endostatin levels were correlated with clinicopathological features and long‐term survival. Results: Serum VEGF levels in patients with HCC were significantly higher than those in controls, but serum levels of endostatin were similar in the two groups. High serum levels of VEGF, but not endostatin, were significantly associated with venous invasion and advanced tumour stage. Patients with a serum VEGF level higher than median (over 245·0 pg/ml) had significantly worse overall and disease‐free survival than those with a lower level (P = 0·012 and P = 0·022 respectively). On multivariate analysis, serum VEGF level was an independent prognostic factor (hazard ratio 1·86 (95 per cent confidence interval 1·10 to 3·92); P = 0·032). Serum endostatin levels did not have significant prognostic influence on overall or disease‐free survival. Conclusion: A high serum level of VEGF is a predictor of poor outcome after resection of HCC. Serum VEGF, but not endostatin, may be a useful prognostic marker in patients with HCC. Copyright © 2004 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- Committee on Research and Conferences Grant of the University of Hong Kong
This publication has 37 references indexed in Scilit:
- Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinomaBritish Journal of Cancer, 2002
- Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implicationsThe Lancet Oncology, 2001
- Clinical Implications of Circulating Angiogenic Factors in Cancer PatientsJournal of Clinical Oncology, 2001
- Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell CarcinomaJournal of Clinical Oncology, 2000
- Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancerUrology, 1999
- Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinomaSurgery, 1999
- Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.Journal of Clinical Oncology, 1998
- Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Vessel Counts and Expression of Vascular Endothelial Growth Factor as Prognostic Factors in Node-Negative Colon CancerArchives of Surgery, 1997
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995